MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-14-2025
OptiNose Cost of Revenue 2011-2026 | OPTN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue OptiNose
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.63 M | 9.26 M | 9.15 M | 7.52 M | 5.29 M | 1.59 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.26 M | 1.59 M | 6.91 M |
Quarterly Cost of Revenue OptiNose
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.75 M | - | 2.06 M | 1.98 M | 1.23 M | - | 2.22 M | 2.57 M | 1.71 M | - | 2.12 M | 2.14 M | 2.01 M | - | 2.41 M | 2.42 M | 1.74 M | - | - | - | - | - | 1.39 M | 1.09 M | 738 K | - | 319 K | 351 K | 200 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.57 M | 200 K | 1.6 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.82 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.04 | -0.12 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.18 | 4.1 % | $ 44.7 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 22.82 | 0.75 % | $ 1.06 B | USA |
 |
Harrow Health
HROW
|
67.9 M | $ 35.03 | 3.03 % | $ 1.29 B | USA |
 |
Evolus
EOLS
|
100 M | $ 4.43 | -5.45 % | $ 286 M | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 1.04 | 1.96 % | $ 24.3 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.87 | -0.29 % | $ 43.4 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.36 | -0.37 % | $ 3.37 M |  Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 6.01 | 2.56 % | $ 237 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.36 | 0.01 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
Tilray
TLRY
|
480 M | $ 6.57 | 1.86 % | $ 4.06 B | Canada |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.28 | -1.2 % | $ 23.8 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Veru
VERU
|
11 M | $ 2.28 | -0.87 % | $ 308 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 13.43 | 1.02 % | $ 16.1 B | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.78 | 1.3 % | $ 3.36 M | USA |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.43 | -1.62 % | $ 320 M | USA |
 |
Perrigo Company plc
PRGO
|
2.76 B | $ 9.65 | 0.89 % | $ 1.34 B | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 0.94 | -2.32 % | $ 101 M | Canada |
 |
Assertio Holdings
ASRT
|
35.4 M | $ 15.95 | 13.93 % | $ 102 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |